DEERFIELD, Ill.--(BUSINESS WIRE)--OVATION Pharmaceuticals, Inc. was granted special status by the U.S. Food and Drug Administration (FDA) for clobazam as an adjunctive treatment for Lennox-Gastaut syndrome (LGS), one of the most severe forms of childhood epilepsy that frequently persists into adulthood. The FDA grants orphan drug designation to products that are intended to treat rare or “orphaned” diseases or conditions such as LGS, which is responsible for approximately three to 10 percent of all childhood epilepsies.1 For LGS patients, as with patients fighting other rare diseases, new treatments are few and far between, making this designation by the FDA of significant importance.
